Go back

Trump Greets Putin as ‘My Friend,’ and the Rise of GLP-1s for Children

11m 15s

Trump Greets Putin as ‘My Friend,’ and the Rise of GLP-1s for Children

President Trump’s recent trip to Asia featured a warm, high-profile meeting with Chinese President Xi Jinping and Russian President Vladimir Putin, emphasizing friendship and diplomatic cooperation despite longstanding tensions. The summit underscores a broader effort to reduce global friction, with Putin asserting that Western isolation efforts have failed. Trump’s persistent outreach to Putin is seen as either a genuine attempt to end the Ukraine war or a personal alignment with authoritarian governance. Meanwhile, Anthropix launched the world’s largest IPO, raising over $80 billion to fund its AI research, reflecting strong investor enthusiasm but also raising ethical concerns about AI’s potential misuse. In U.S. politics, Democrats selected Hakeem Jeffries as House Speaker, marking a historic milestone as the first Black Speaker, while Senate leadership remains contested. A major debate has emerged over using GLP-1 drugs for children aged 6–11, with medical experts divided on the risks to growth and development versus the benefits in combating severe obesity. Globally, education systems face new challenges as students use smartphones and AI tools to cheat in exams, prompting countries like South Korea and the U.S. to implement extreme countermeasures—including bounties and AI-based detection systems—highlighting the evolving struggle between technology and academic integrity. These developments illustrate both progress and profound risks in technology, geopolitics, and public health.

Transcription

1788 Words, 10199 Characters

English
From The New York Times, it's The Headlines. I'm Tracey Mumford. Today's Thursday, November 19th. Here's what we're covering. It's an honor to be with you. You're my friend, and we have a very special relationship. And I think as long as you and I are in charge of things, we'll never have a problem. In China, President Trump and Chinese President Xi Jinping have put on a warm display. A red carpet welcome at the airport, and the two going in for a hug on the tarmac. Trump has said he does not plan to bring up the most high-profile issue between the two countries right now, the spying scandal that engulfed NVIDIA. Instead, Trump is expected to try and smooth over economic tensions and keep the trade war from flaring back up. Trump's whirlwind trip to Asia isn't just about China, though. The centerpiece was actually a meeting today between Trump, Xi Jinping, and Xi Jinping. Xi and Russian President Vladimir Putin, a first-of-its-kind summit. Trump greeted both Xi and Putin as, quote, my friend, saying the three leaders had a special responsibility to maintain communication. While it was historic and important for all three of the leaders, it was certainly most important for Vladimir Putin. Paul Sony, the Times' Moscow bureau chief, has been reporting from the summit, which Putin pushed for. Paul says the Russian president, Xi Jinping, used the meeting to declare that efforts to isolate his country after the invasion of Ukraine have failed. And the image of Putin standing side-by-side with the two most powerful leaders in the world only underscored that. Putin will soon get another opportunity in this same vein. President Trump has invited him to attend the G20 summit in Miami next month. If we ask ourselves, why has Donald Trump tried so hard to bring Putin back into the fold, I think the generous explanation, is that he thought he could use his friendliness with Putin to try to end the war in Ukraine. He came back into office saying that he would end the war in 24 hours, but nearly two years into his second term, in many ways, negotiations are still at the starting line. So that effort so far hasn't borne fruit. I think the less generous explanation is that Trump personally has an affinity for authoritarian rule. He sees something he likes in Vladimir Putin and Xi Jinping. And in some ways, he wants to stand together with them and say, we are these strong men who rule the world. On Wall Street, Anthropix going public. This morning, it will begin trading on the Nasdaq under the symbol A-N-T. It is hitting the stock market after pulling off the largest initial public offering of all time yesterday. It sold over $80 billion of its shares, beating the record. It was the record set by Elon Musk's SpaceX back in June. Here are four quick things to know about the IPO. One, this is the general public's first chance to invest in one of AI's frontier labs, the companies shaping the AI models behind the boom. And because it is the first, it's being viewed as a key test of investors' appetite for the whole industry. Based off yesterday's investments, that appetite is high at the moment. Two, part of the reason Anthropix is going public right now is because building AI requires so much money to pay for computer chips, data processing power, electricity, etc. The company has a lot of debt. Raising tens of billions of dollars certainly helps with that. Three, even as Anthropix is trying to win over investors, the company itself has acknowledged there are major risks to the technology it's building. Its IPO fund? Its IPO filing warned that its products had the potential to bring about disasters in the hands of authoritarians or if humans lose control of the technology. And the last thing to know, Americans will be affected by Anthropix's stock market performance even if they do not own a share, don't want to own a share, or don't even use the tech. That's because of the sheer size of Anthropix and the even greater amount of investment poured into AI in general. Essentially, AI has been characterized, the U.S. economy. So far, that has meant a lot of shared gains, but it also means shared risks. In Washington yesterday, Our job is to fight MAGA extremism, not each other, and to get big things done for the American people. Democrats voted to nominate Hakeem Jeffries of New York to be Speaker of the House. There was. There was some resistance from progressives in the party who said they were fed up with the Democratic establishment and had accused Jeffries of being beholden to corporate interests. In the end, though, Democrats voted overwhelmingly for Jeffries, 251-11, according to a person who attended the confidential count. Jeffries still needs to make it through a vote in the House in January, which shouldn't be an issue with the Democrats' big majority. That vote would make him the first Black lawmaker to ever hold the role of Speaker of the House and put him second in line to the presidency. Meanwhile, the question of who will lead the Senate is more up in the air. The Democrats were given a chance. We need to earn people's trust. And I don't think you do that by simply going back to business as usual. The left-leaning Senator Chris Van Hollen of Maryland is challenging Chuck Schumer for majority leader, arguing that the Democrats' sweeping success in the mayoral election would be a waste of time. was proof people are hungry for change. For his part, Schumer, a moderate who has led Democrats in the Senate for almost a decade, has argued he should keep the job since he helped recruit many of the candidates who made up the blue wave. Both lawmakers are now working to win over their colleagues ahead of a secret ballot vote that's scheduled for December 1st. Over the last decade, the rapid rise of GLP-1 drugs has upended how obesity is treated in the U.S. According to a recent Gallup survey, about 15% of adults in the country say they've used one of those weight-loss drugs. Now, the results of a new, closely-watched clinical trial are paving the way for them to be prescribed to young children. In the study released this week, kids aged 6 to 11, many with severe obesity, were given a GLP-1. After about a year and a half, nearly 40% of them no longer had obesity. I spoke to almost a dozen doctors, and they all agree that pediatric obesity is a massive problem and we need to be doing more to address it. But the question is whether the risks outweigh the benefits for these medications, and people are really deeply divided. Dani Bloom is a health reporter at The Times. So there are some people who are really excited about the prospect of using these medications for children. They say that they have wanted a really powerful tool to address pediatric obesity, especially for children who are severely obese, and that hasn't really existed until this point. And there are people who say, if you could stop a child from developing even more severe obesity, from going on to have these complications that can follow them for the rest of their lives, wouldn't you want to intervene as early as possible? On the other hand, you have a group of doctors and researchers who are pretty concerned about the use of these medications in children who are so young, because there are, there are a ton of open questions when it comes to how the drugs could impact puberty, children's growth, children's height. It's really critical for children to have proper nutritional intake at this stage in their lives. When you're talking about ages 6 through 12, that's when your bones are developing, that's when you're growing. And these are medications that obliterate your appetite. That's the primary mechanism through how they work. And so some of these doctors say maybe it's not the best idea to give these powerful medications that are really strong appetite suppressants to children. to children who are still growing. Danny says in terms of next steps, the drug maker behind Ozempic and Wagovi is planning to ask the FDA to approve the medication for kids age 6 to 11. It is already approved for children 12 and up. And finally, this morning across South Korea, every phone in the country, started buzzing in unison. It was the kind of emergency alert you might expect during a natural disaster or a wartime attack. But this was something different. Officials were trying to root out would-be cheaters on the country's high-stakes college entrance exam. The Ministry of Education said after the alert first went off, 22 test takers were caught with hidden phones. This is just one of the many extreme measures the government has been using has gone to to tackle the cheating problem. That includes making students put stickers on their shirt buttons to cover up any tiny cameras that might be hidden in them and offering a $75,000 bounty to anyone who outs a cheater. And South Korea is not alone. Authorities around the world are locked in a cat-and-mouse game with students as new technologies have supercharged the problem. We're not talking about sneaking a note card up your sleeve anymore. Now, you can just quietly use your phone to snap photos of a test question and get ChatGPT to give you the answer. In some places, students have been caught using AI-powered smart glasses on big exams. And in the U.S., the College Board, which oversees the SAT, said that some test takers spent $500 on a software program that let them bypass restrictions on their laptops and showed them which multiple-choice answer to select. The program even allegedly tried to help students cover their tracks by reminding them not to rush. Take your time with each question, as if you're actually thinking it through. So how do you fight that? The College Board had to buy its own copy of the cheating software to try and understand exactly how it works to make its own system stronger. Essentially, know thine enemy. Those are the headlines. Today on The Daily, what we do and don't know about the cascade of recent tech outages that have rattled the country. You can find that in the New York Times app or wherever you get your podcasts. I'm Tracy Mumford. We'll be back tomorrow with the latest and the Friday News Quiz.

Podcast Summary

Key Points:

  1. President Trump and Chinese President Xi Jinping held a warm, friendly meeting in China, avoiding the high-profile spying scandal involving NVIDIA, instead focusing on easing economic tensions.
  2. Trump hosted a historic tripartite summit with Xi Jinping and Russian President Vladimir Putin, where he called both leaders “my friend,” reinforcing a rare alliance aimed at stabilizing global politics.
  3. Putin used the summit to assert that Western efforts to isolate Russia over its Ukraine invasion have failed, signaling a shift in Russia’s geopolitical positioning.
  4. Trump’s outreach to Putin may stem from a desire to end the war in Ukraine through diplomacy, though progress remains minimal, or from a personal affinity for authoritarian leadership styles.
  5. Anthropix launched the largest IPO in history, raising over $80 billion, marking the first public investment in a frontier AI lab and signaling strong investor confidence in AI technology.
  6. Anthropix’s IPO highlights both the financial growth and risks of AI, including potential misuse by authoritarian regimes or uncontrolled technological outcomes.
  7. The U.S. political landscape saw Democrats narrowly nominate Hakeem Jeffries as House Speaker, making him the first Black Speaker and setting a precedent for diversity in leadership.
  8. Concerns over pediatric use of GLP-1 drugs for children aged 6–11 are intense, with doctors divided between potential benefits in treating severe obesity and risks to growth and puberty.

Summary:

President Trump’s recent trip to Asia featured a warm, high-profile meeting with Chinese President Xi Jinping and Russian President Vladimir Putin, emphasizing friendship and diplomatic cooperation despite longstanding tensions. The summit underscores a broader effort to reduce global friction, with Putin asserting that Western isolation efforts have failed. Trump’s persistent outreach to Putin is seen as either a genuine attempt to end the Ukraine war or a personal alignment with authoritarian governance.

Meanwhile, Anthropix launched the world’s largest IPO, raising over $80 billion to fund its AI research, reflecting strong investor enthusiasm but also raising ethical concerns about AI’s potential misuse. S. politics, Democrats selected Hakeem Jeffries as House Speaker, marking a historic milestone as the first Black Speaker, while Senate leadership remains contested.

A major debate has emerged over using GLP-1 drugs for children aged 6–11, with medical experts divided on the risks to growth and development versus the benefits in combating severe obesity. S. to implement extreme countermeasures—including bounties and AI-based detection systems—highlighting the evolving struggle between technology and academic integrity.

These developments illustrate both progress and profound risks in technology, geopolitics, and public health.

FAQs

The summit was historic as the first meeting between Trump, Xi Jinping, and Putin. It highlighted efforts to strengthen international communication, with Putin asserting that efforts to isolate Russia have failed.

Trump has sought to build a relationship with Putin to potentially end the war in Ukraine. Some analysts suggest he also personally admires authoritarian leaders and wants to associate with them as powerful world figures.

Anthropix is an AI-focused company going public with a record $80 billion IPO. It marks the first opportunity for the public to invest in a leading AI research lab and signals strong investor confidence in AI technology.

The company's IPO filing warns that its AI products could be misused by authoritarians or lead to disasters if humans lose control of the technology, highlighting significant ethical and safety concerns.

Yes, because Anthropix is one of the largest AI investments and AI as a whole is deeply integrated into the U.S. economy, so its performance affects broader economic and market trends.

Yes, a new clinical trial shows that nearly 40% of children aged 6 to 11 with severe obesity no longer have obesity after one year and a half of treatment, prompting discussions about pediatric use.

Chat with AI

Loading...

Pro features

Go deeper with this episode

Unlock creator-grade tools that turn any transcript into show notes and subtitle files.